Regenics develops a new wound healing device (Collex™) in addition to Vernex®. Collex™ is in exploratory pre-clincial phase. Collex™ is a 3D-bioprinted collagen producing alginate patch/bandaid. The Collex™is under development for a CE-marked (EU) wound healing Medical Device, class III, followed by a 510k (US) clearance post CE-marking. 

The intended use for Collex™ is assumed to be:

  • Partial and full-thickness wounds
  • Trauma wounds (abrasions, lacerations, second-degree burns, skin tears)
  • Pressure ulcers
  • Chronic vascular ulcers
  • Diabetic ulcers
  • Surgical wound (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence)
  • Draining wounds

Collex™  is beeing developed by Regenics with support from a.o. Chalmers 3D-bioprinting Centre in Gothenburg, Sweden.  The risk in the project is high, the prototype has not been completed and the remaining development time is at least 3 tears, including clinical testing. Collex™ is produced by 3D-bioprinting large surface patches with embedded collagen producing human skin fibroblasts activated by salmon roe extract to secrete collagen directly from the 3D-bioprinted patch. The product is contemplated to be a sterile patch for hard to heal large wounds. 

For more info on Collex™:

 

 

Scientifically documented and patented claims in wound healing:

  • COLLEX™ is a registered trademark
  • COLLEX™ will be a collagen producing wound patch 
  • COLLEX™ will be secreting collagen from a 3-bioprinted patch
  • COLLEX™ is in esxploratory development and pilot testing
  • COLLEX™ will be developed as a class III medical device
  • COLLEX™ will be developed for advanced wound treatment

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.